High-stability T-cell receptor and preparation method and application thereof
The present invention provides a high-stability T cell receptor. The T cell receptor has mutations in its hydrophobic core domain causing the enhancement of stability thereof. The present invention additionally provides a preparation method and an application of the T-cell receptor.
1. A mutated T cell receptor (TCR) that is a single-chain TCR, comprising a mutated TCR α chain variable domain, a mutated TCR β chain variable domain, and a flexible peptide linker linking the variable domains,
wherein the mutated α chain variable domain amino acid sequence is selected from the group consisting of SEQ ID NOs: 35, 99, and 101;
wherein the mutated β chain variable domain amino acid sequence is selected from the group consisting of SEQ ID NOs: 36, 100, and 102;
wherein the mutated TCR has a stability at least 80% higher than that of the corresponding wild-type TCR with wild-type hydrophobic core, wherein the term “stability” refers to protein stability, and wherein compared with the original wild-type TCR, the mutated TCR has one or more characteristics selected from the group consisting of higher resistance to unfolding, higher resistance to inappropriate or undesirable folding, stronger renaturability, stronger expression ability, higher protein renaturation yield, and increased thermal stability.
2. The mutated TCR of claim 1 , wherein CDR regions of the mutated TCR are same as the CDR regions of the corresponding wild-type TCR.
3. The mutated TCR of claim 1 , wherein the mutated TCR is water-soluble.
4. The mutated TCR of claim 1 , wherein a conjugate is bound to the C-terminal or N-terminal of the α chain and/or β chain of the mutated TCR.
5. The mutated TCR of claim 4 , wherein the conjugate bound to the mutated TCR is a detectable marker, a therapeutic agent, or a combination thereof.
6. The mutated TCR of claim 5 , wherein the therapeutic agent bound to the mutated TCR is an anti-CD3 antibody linked to the C- or N terminal of the α chain or β chain of the mutated TCR.
7. The mutated TCR of claim 1 , wherein the mutation is screened out by phage display technology.
8. A TCR complex comprising one or more mutated TCR molecules of claim 1 .
9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective dosage of the mutated TCR of claim 1 .
10. An isolated cell presenting the mutated TCR of claim 1 .
11. The mutated TCR of claim 1 , wherein the mutated α chain variable domain and the mutated β chain variable domain are selected from the group consisting of:
(a) α chain variable domain having amino acid sequence of SEQ ID NO:35 and β chain variable domain having amino acid sequence of SEQ ID NO:36;
(b) α chain variable domain having amino acid sequence of SEQ ID NO:99 and β chain variable domain having amino acid sequence of SEQ ID NO:100; and
(c) α chain variable domain having amino acid sequence of SEQ ID NO:101 and β chain variable domain having amino acid sequence of SEQ ID NO:102.